Atomwise vs Insitro

Insitro has a disclosed valuation of $2.2B, while Atomwise's valuation is not publicly available, making a direct size comparison difficult. Insitro employs 300 people.

Insitro has raised more in total funding at $743M, compared to Atomwise's $219M — a gap of $524M. Combined, the two companies have completed 6 known funding rounds.

Insitro leads with an Awaira Score of 73/100, while Atomwise sits at 53/100. That 20-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Atomwise was founded by Abraham Heifets in 2012. Insitro was founded by Daphne Koller in 2018. Visit each company's profile on Awaira for a full founder biography.

Atomwise: Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform applies machine learning algorithms to screen vast chemical libraries and predict molecular interactions, enabling faster identification of promising compounds for various therapeutic areas including oncology, infectious diseases, and genetic disorders. The company has secured $219 million in total funding and operates at the Series B stage, though its current valuation remains undisclosed. Atomwise's approach combines physics-based molecular modeling with machine learning to simulate how potential drugs interact with disease targets. The platform has been applied to multiple drug discovery projects across both internal programs and partnerships with pharmaceutical companies and research institutions. Atomwise competes in the growing computational drug discovery sector alongside companies utilizing AI for pharmaceutical development. The company's technology addresses significant pain points in drug development, including extended timelines and high failure rates. Its trajectory reflects the increasing adoption of AI-driven approaches in healthcare and pharmaceutical industries, positioning it within a broader trend toward computational acceleration of biomedical research and development processes. Atomwise applies physics-informed machine learning to molecular simulation for drug discovery, combining computational chemistry with AI to accelerate preclinical pharmaceutical development. Insitro: Insitro is an AI-driven drug discovery company founded in 2018 that applies machine learning to accelerate pharmaceutical development. The company combines computational biology, artificial intelligence, and wet-lab experimentation to identify and validate drug targets more efficiently than traditional methods. Insitro's platform uses proprietary algorithms to analyze complex biological data, predict drug efficacy and safety profiles, and optimize candidate selection across therapeutic areas including metabolic disease, oncology, and immunology. The company has raised $743 million across multiple funding rounds, achieving a valuation of $2.2 billion as of its Series C stage. This positions Insitro among well-capitalized AI healthcare startups addressing the structural inefficiencies in drug discovery. The company partners with pharmaceutical institutions to apply its technology to their pipelines, utilizing both internal discovery programs and collaborations. Insitro's competitive approach differs from pure software platforms by integrating experimental validation, reducing the translation gap between computational predictions and real-world drug performance. The company operates in a crowded but expanding market of AI drug discovery platforms competing against both established pharma AI initiatives and other venture-backed startups. Its growth trajectory reflects investor confidence in AI-enabled drug discovery models, though clinical validation remains ongoing for internally developed candidates. Insitro uniquely combines machine learning with integrated wet-lab capabilities rather than operating as pure software, bridging computational predictions to experimental validation.

Atomwise got there first, launching in 2012 — that's 6 years of extra runway. Insitro didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Atomwise has about 75 employees; Insitro has about 300. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Atomwise and Insitro compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.